I had the privilege of meeting Professor Jill Adler-Moore in 2008, the year I joined Gilead. She came to Portugal twice and in 2010 she toured in through Lisbon and Oporto to interested Doctors to learn about its legacy. We produced a book to go along with her slide decj, that I attach, and in the introduction, she mentioned, and I quote:
“In summary, it is very gratifying to know that AmBisome has continued to help treat many people, decreasing morbidity and mortality. I am humbled by having had the opportunity to be a part of something that has had such a positive impact on healthcare and has demonstrated convincingly that there is a place for liposome delivery of drugs.” (JAM)
30 Years and counting, AmBisome continues to be this beacon of hope to so many patients, and it is our job to make sure her message is continuously transmitted as we are the torch to enlightened health care workers around the world of this great invention from this Great Lady.
Thank you very much Jill,
I had the privilege of meeting Professor Jill Adler-Moore in 2008, the year I joined Gilead. She came to Portugal twice and in 2010 she toured in through Lisbon and Oporto to interested Doctors to learn about its legacy. We produced a book to go along with her slide decj, that I attach, and in the introduction, she mentioned, and I quote:
“In summary, it is very gratifying to know that AmBisome has continued to help treat many people, decreasing morbidity and mortality. I am humbled by having had the opportunity to be a part of something that has had such a positive impact on healthcare and has demonstrated convincingly that there is a place for liposome delivery of drugs.” (JAM)
30 Years and counting, AmBisome continues to be this beacon of hope to so many patients, and it is our job to make sure her message is continuously transmitted as we are the torch to enlightened health care workers around the world of this great invention from this Great Lady.
Thank you very much Jill,
